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Background:  Rapid  antigen  detection  tests  (RADTs)  are  increasingly  used  to detect  inﬂuenza  viruses
and  respiratory  syncytial  virus  (RSV).  However,  their  sensitivity  and  speciﬁcity  are  a matter  of  debate,
challenging  their clinical  usefulness.
Objectives:  Comparing  diagnostic  performances  of BinaxNow  Inﬂuenza  AB® (BNI)  and BinaxNow  RSV®
(BNR),  to  those  of real-time  reverse  transcriptase  PCR  (RT-PCR),  virus  isolation  and  direct  immunoﬂuo-
rescence  (D-IF)  in  paediatric  patients.
Study  design:  Between  November  2005  and  September  2013,  521  nasal  washings  from  symptomatic
children (age <5  years)  attending  our  tertiary  care  centre  were  tested,  with  a combination  of  the  respective
assays  using  RT-PCR  as  gold  standard.
Results:  Sensitivity,  speciﬁcity,  positive  predictive  value  (PPV)  and negative  predictive  value  (NPV)  of BNI
were 69%  (conﬁdence  interval  [CI]  [51–83]),  96%  [94–97],  55%  [39–70]  and  98%  [96–99] respectively.  Of
eleven  false-negative  samples,  RT-PCR  Ct-values  were  higher  than  all RT-PCR  positive  test results  (27 vs
22, p  =  0.012).  Of twenty  false-positive  samples,  none  were  culture  positive  and two  tested  positive  in
D-IF.
Sensitivity,  speciﬁcity,  PPV  and  NPV  for BNR  were  79%  [73–85],  98%  [96–99],  97% [93–99] and  88%
[84–91]. Of  the  42  false-negative  samples  the  median  Ct-value  was  higher  than  that  of  all  RT-PCR  positive
samples  (31  vs  23, p < 0.0001).  Five false-positive  samples  were  detected.  Three  of  these  tested  positive
for  RSV  in  virus  isolation  and  D-IF.
Conclusions:  RADTs  have  a high  speciﬁcity  with  BNR  being  superior  to  BNI.  However,  their  relative  low
sensitivity  limits  their  usefulness  for clinical  decision  making  in a tertiary  care  paediatric  hospital.
© 2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Background
Inﬂuenza viruses and respiratory syncytial viruses (RSV) cause
cute respiratory tract infections (ARTIs) in children, being a lead-
ng cause of hospitalization [1–3]. Identiﬁcation of both viruses
s important for disease management, as the presence of these
nfections may  require speciﬁc treatment (i.e. oseltamivir) and
ospital containment measures. The current gold standard for
etection of these viruses is real-time reverse transcriptase PCR
RT-PCR) [4]. This is however not performed in all hospitals, as it
∗ Corresponding author at: Research Center for Emerging Infections and Zoonoses
RIZ), University of Veterinary Medicine, Bünteweg 17, 30559 Hannover, Germany.
E-mail address: Albert.Osterhaus@tiho-hannover.de (A.D.M.E. Osterhaus).
ttp://dx.doi.org/10.1016/j.jcv.2016.03.022
386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
requires a molecular diagnostic laboratory with specialized person-
nel and equipment. Instead, rapid antigen detection tests (RADTs)
are used as these assays are easier and cheaper to perform and less
time-consuming [5–7]. The performance of these tests depends on
factors like time between disease onset and sampling, quality and
type of specimen and epidemiological parameters [8]. Diagnos-
tic value and clinical usefulness of RADTs for inﬂuenza diagnosis
vary greatly [5–7,9–12]. This prompted us to evaluate the diag-
nostic performance of the routinely used RADTs (manufactured by
Alere BinaxNOW®) for these two viruses as used in our tertiary care
paediatric hospital.nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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. Objectives
Comparing diagnostic performances of two  RADTs, BinaxNow
nﬂuenza AB® (BNI) and BinaxNow RSV® (BNR), with those of RT-
CR in samples of paediatric patients attending our tertiary care
entre with ARTIs for a period of almost eight consecutive years.
iscrepant data were subsequently compared with those of virus
solation and direct immunoﬂuorescence (D-IF) assays.
. Study design
This study was conducted from November 2005 through
eptember 2013, we identiﬁed paediatric patients between 0 and 5
ears who attended Erasmus MC-Sophia’s emergency department,
ut-patient-clinic and those who were hospitalized in this period.
o analyse the performance of the BNI and BNR compared to RT-PCR
e selected 521 nasal washings of 489 patients with a median age of
 months (minimum 0.03–maximum 58 months, lower interquar-
ile range 1.6–upper interquartile range 9.8) and 55% (268/489)
ere male. Nasal washings were obtained during routine clini-
al practice in symptomatic children and were tested immediately
fter sampling by trained laboratory personnel using all four diag-
ostic methods. Multiple samples from the same patient were
ncluded in our analysis. Therefore patients are referred to as cases.
ata regarding gender, age and hospital admission were obtained
rom the electronic patient ﬁles.
.1. Ethics
Data collection and analyses were conducted on anonymized
amples, which does not require further medical ethics review as
onsented by our Medical ethical board (MEC-2015-306).
. Tests
.1. RT-PCR gold standard
All nasal washings were tested for the presence of selected
iruses by means of RT-PCR with primers and probes sets used in
he routine setting of our department [13]. In short, RNA and DNA
ere extracted using MagnaPureLC (Roche Diagnostics, Almere, the
etherlands) and the total nucleic acid isolation kit. The extractions
ere internally controlled by addition of a known concentra-
ion of phocine distemper virus (PDV) and phocine herpes virus
PHV). Uni-plex RT-PCR was used to detect RSV-A, RSV-B, human
hinovirus (HRV), parainﬂuenza virus (PIV) type 3 (PIV-3), ade-
ovirus (ADV), and human bocavirus (HBoV). Duplex reactions
ere performed combining inﬂuenza A virus and PDV, inﬂuenza
 virus and human coronavirus (HCoV) OC43 (HCoVOC43), human
etapneumovirus (HMPV) and PIV-2, HCoV229E and PIV-4, and
CoVNL63 and PIV-1. A cycle threshold value (Ct-value) of <40 was
eﬁned positive for any virus. RT-PCRs were developed in-house for
nﬂuenza viruses and RSV-A and validated [13]. RSV-B primers and
robes were used as reported by Dewhurst-Maridor et al. [14].
.2. Rapid antigen detection tests (RADTs)
Alere BinaxNOW® Inﬂuenza A and B (BNI) and Alere
inaxNOW® RSV (BNR) (Scarborough, Maine, USA) are commer-
ially available in vitro immunochromatographic assays for the
ualitative detection with monoclonal antibodies directed against
nﬂuenza A and B virus nucleoproteins and RSV fusion protein anti-
en, respectively. Nasal washings were obtained using standard
rotocols and rapid antigen testing was performed as described by
he manufacturer. For our analyses the test results of BNI inﬂuenzacal Virology 79 (2016) 12–17 13
A and inﬂuenza B were combined into a single inﬂuenza BNI dataset
as inﬂuenza B was not encountered frequently with only four
inﬂuenza B BNI positive samples, two of which were inﬂuenza B
RT-PCR positive.
4.3. Virus isolation assay
Virus isolation assays were always performed in combination
with D-IF. Madin-Darby Canine Kidney (MDCK) cell line (NBL-2)
(ATCC® CCL-34TM) and the human cell line HEp-2 (ATCC® CCL-
23TM) were used to isolate inﬂuenza viruses and RSV respectively.
Virus cultures were regularly checked for cytopathic effect by light
microscopy. Immunoﬂuorescence with ﬂuorescein isothiocyanate
(FITC) labeled monoclonal antibodies was  used to conﬁrm the pres-
ence of inﬂuenza virus or RSV [15].
4.4. Direct immunoﬂuorescence (D-IF) assays in clinical
specimens
Cells were isolated from nasal washings, dried on microscope
slides, and ﬁxed with acetone. Subsequently, cells were stained
with FITC conjugated monoclonal antibodies against inﬂuenza A
virus, inﬂuenza B virus or RSV (IMAGENTM Inﬂuenza A and B and
IMAGENTM RSV, Hampshire, United Kingdom). Specimens were
incubated with FITC-conjugated antibodies for 15 min  at 37 ◦C, sub-
sequently excess reagent was  washed off with phosphate buffered
saline. The stained area was  then mounted and viewed by ﬂuores-
cent microscopy.
4.5. Comparison between tests
The focus of our study was to compare data obtained with two
RADTs, BNI and BNR with those obtained by RT-PCR as gold stan-
dard. We  deﬁned false-negative tests as those for which the rapid
test was negative and the gold standard RT-PCR positive; a false-
positive test result was  deﬁned if the rapid test tested positive and
the gold standard RT-PCR tested negative. We compared the avail-
able Ct-values in all respective categories of samples and analysed
whether there was  an association between Ct-values and RADTs
results and hospitalization. For inﬂuenza all Ct-values were avail-
able, for RSV Ct-values were available for 183/204 (90%) of the
performed tests. Missing Ct-values were from samples tested in
2005 and 2006 when routine input of Ct-values in our laboratory
system was  not yet performed and digital documentation was not
available. Finally, false-negative and false-positive test results were
compared to test results obtained with the other virus detection
methods: virus isolation and D-IF assays.
4.6. Statistical analyses
The main outcomes of this study were the sensitivity, speciﬁcity,
positive predictive value (PPV) and negative predictive value (NPV)
of the BNI and BNR rapid test results compared to RT-PCR during
the total study period and during viral season (October 1st through
March 31st). Ct-values were compared with Mann-Whitney U tests.
5. Results
5.1. Sensitivity and speciﬁcity of BNI
Of 521 nasal washings both inﬂuenza RT-PCR and BNI data were
available. Most were obtained between September and March (see
Supplemental data Figs. S1 and S2 in the online version at doi: 10.
1016/j.jcv.2016.03.022). Of these, 35 cases tested positive with RT-
PCR (35/521, 7%, median Ct-value 22 [range] [17–39]) whereas 44
tested positive in the BNI (44/521, 8%). Of the 35 RT-PCR positive
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Table 1
Sensitivity, speciﬁcity, positive predictive value (PPV) and negative predictive value (NPV) of rapid antigen detection test BinaxNOW inﬂuenza AB® and BinaxNOW RSV®
compared to gold standard RT-PCR tested in nasal washings of children between 0 and 5 years at Erasmus MC-Sophia from 2005 to 2013.
Rapid antigen detection tests Sensitivity (%) [95% conﬁdence interval; CI] n Speciﬁcity (%) [95% CI] n PPV (%) [95% CI] n NPV (%) [95% CI] n
BinaxNow Inﬂuenza AB® vs RT-PCR n = 521 68.6 [51–83] 24/35 95.8 [94–97] 466/486 54.5 [39–70] 24/44 97.7 [96–99] 466/477
BinaxNow RSV® vs RT-PCR n = 514 79.4 [73–85] 162/204 98.4 [96–99] 305/310 97 [93–99] 162/167 88 [84–91] 305/347
Samples obtained in respiratory virus season
BinaxNow Inﬂuenza AB® vs RT-PCR n = 436 66.7 [48–82] 22/33 
BinaxNow RSV® vs RT-PCR n = 428 80 [74–85] 160/200 
Fig. 1. (A) Ct-values compared for BinaxNOW inﬂuenza AB® (BNI) rapid test positive
results and rapid test negative results for inﬂuenza in children between 0 and 5 years
at  Erasmus MC-Sophia from 2005 to 2013. (B) Ct-values compared for BinaxNOW
RSV® (BNR) rapid test positive results and rapid test negative results for RSV in
c
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children between 0 and 5 years at Erasmus MC-Sophia from 2005 to 2013. The
umber between () refers to all RT-PCR positive results, for 21 samples no Ct-values
ere available.ases 24 also tested positive in the BNI (24/35, 69%, median Ct-
alue 21 [17–31]). The eleven RT-PCR positive (median Ct-value 27
18–39]) and BNI negative cases were considered false-negative
ases (11/521, 2%). Of the 486 RT-PCR negative cases, 20 were95.3 [93–97] 384/403 53.7 [37–69] 22/41 97.2 [95–99] 384/395
98 [96–100] 224/228 98 [94–99] 160/164 85 [80–89] 224/264
BNI positive, and were therefore considered false-positive cases
(20/521, 4%). Considering RT-PCR as the gold standard, it may  be
concluded that the BNI has a relatively low sensitivity of 69% (con-
ﬁdence interval (CI): [51–83]) (24/35), a high speciﬁcity of 96% [CI:
94–97] (466/486), a low PPV of 55% [CI: 39–70] (24/44) and a high
NPV of 98% [CI: 96–99] (466/477) (Table 1). We also calculated these
parameters only with samples obtained in the period from October
1st through March 31st, when respiratory viruses are more preva-
lent in the Netherlands. Sensitivity and speciﬁcity decreased with
2% and 1% respectively (69%–67% and 96%–95%). PPV and NPV both
decreased with 1% from 55% to 54% and 98%–97% respectively.
5.2. Sensitivity and speciﬁcity of BNR
Of 514 nasal washings both RSV RT-PCR and BNR data were
available. Of these, 204 cases were RSV RT-PCR positive (204/514,
40%) with Ct-values available for 183 samples ranging from 14
to 39 (median Ct-value 23) and 167 were BNR positive (167/514,
32%) (Table 1). Hundred sixty-two samples were RT-PCR posi-
tive and BNR positive (162/514, 32%, median Ct-value 21 [14–35],
no Ct-value available n = 15). Forty-two cases were considered
false-negative (42/514, 8%, median Ct-value 31 [22–39], no Ct-value
available n = 6). Of the 310 RT-PCR negative cases, ﬁve were BNR
positive and considered false-positive cases (5/514, 1%). The over-
all test performance of BNR was relatively high with a sensitivity of
79% [CI: 73–85] (162/204), speciﬁcity of 98% [CI: 96–99] (305/310),
PPV of 97% [CI: 93–99] (162/167) and NPV of 88% [CI: 84–91]
(305/347). We  also calculated these parameters during the respira-
tory virus season (October–March) and sensitivity increased with
1% (79%–80%), but the speciﬁcity remained the same (98%). PPV
increased with 1% (from 97% to 98%) and NPV decreased with 3%
from 88% to 85% respectively.
5.3. Discordant samples
5.3.1. False-negative rapid antigen detection tests
From the eleven false-negative BNI cases, inﬂuenza virus was
successfully isolated in six cases (6/11, 55%, median Ct-value 25
[17–27]), three of which were also inﬂuenza D-IF positive. By means
of RT-PCR, virus isolation or D-IF 7/11 (63%) samples tested positive
for another virus, most frequently RSV (n = 3) or adenovirus ADV
(n = 3) (see Supplemental Table 1a in the online version at doi: 10.
1016/j.jcv.2016.03.022).
BNR results were considered false-negative in 42 cases, in 25
(60%) of those RSV was  cultured successfully. In these 25 cases the
Ct-values ranged from 22 to 39 with a median of 32. In addition,
in 20/42 (48%) cases, RSV D-IF tested positive (median Ct-value 29
[22–37]). Co-infections were found in 16/42 (38%) cases and most
often HRV (n = 7). In four cases BNI tested positive for inﬂuenza,
which could be conﬁrmed for three samples by RT-PCR (see Sup-
plemental Table 1b in the online version at doi: 10.1016/j.jcv.2016.
03.022).
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cig. 2. (A) Ct-values in relation to BinaxNOW inﬂuenza AB® (BNI) rapid test results
o  2013. ns = no statistical signiﬁcant difference. (B) Ct-values in relation to BinaxN
t  Erasmus MC-Sophia from 2005 to 2013. ns = no statistical signiﬁcant difference.
.3.2. False-positive rapid antigen detection tests
Of the 20 inﬂuenza false-positive cases, six tested positive in
NR (6/20, 30%). Moreover, six cases tested RSV RT-PCR positive
6/20, 30%) of which ﬁve were also BNR positive. In eight samples
nother respiratory virus than inﬂuenza virus or RSV was  detected
ith RT-PCR (8/20, 40%). For two samples the D-IF was positive
or inﬂuenza, in accordance with the BNI, but for both virus isola-
ion did not yield inﬂuenza virus (see Supplemental Table 2a in the
nline version at doi: 10.1016/j.jcv.2016.03.022).
For BNR only ﬁve false-positive cases were found. Three of these
ere RSV positive in virus isolation and D-IF (3/5, 60%). One case
ested negative in all methods except for BNI (see Supplemental
able 2b in the online version at doi: 10.1016/j.jcv.2016.03.022).
he sensitivity (80%), speciﬁcity (99%) and PPV (99%) increased if we
onsidered the three RSV positive virus isolations as true-positive
ases, resulting in only two false-positive cases (2/514, 0,4%).ospitalization of children between 0 and 5 years at Erasmus MC-Sophia from 2005
SV® (BNR) rapid test results and hospitalization of children between 0 and 5 years
5.3.3. Test results and hospitalization
Of all 521 patients tested for BNI and BNR 361 patients (361/521,
69%) were hospitalized. Hospitalization rates were 16/24 (67%) and
115/162 (71%) for true-positive BNI and BNR cases respectively.
False-negative test results did not seem to have a major impact
on hospitalization with hospitalization rates of 7/11 (64% vs 69%,
p = 1) and 25/42 (60% vs 71%, p = 0.1912) for BNI and BNR test results
respectively (Table 2).
Comparing the Ct-values of the respective categories, BNI
and BNR cases that were false-negative displayed overall higher
Ct-values (p = 0.012 vs p < 0.0001) (Fig. 1A and B). However,
no differences were found in Ct-values of hospitalized and
non-hospitalized patients within the respective case groups (p > 0.5
for both BNI and BNR) (Fig. 2A and B). The BNI test result did not dif-
ferentiate for severe disease with three of the false-negative cases
admitted to the paediatric intensive care unit (PICU), but also three
16 F.M. Moesker et al. / Journal of Clini
Table 2
BinaxNow Inﬂuenza AB® (BNI) and BinaxNOW RSV® (BNR) test results in relation to
hospitalization of children between 0 and 5 years at Erasmus MC-Sophia from 2005
to 2013.
BNI True-positive (%) False-negative (%) False-positive (%)
Admitted 16/24 (67) 7/11 (64) 16/20 (80)
Not admitted 8/24 (33) 4/11 (36) 2/20 (10)
Unknown – – 2/20 (10)
BNR
Admitted 115/162 (71) 25/42 (60) 5/5 (100)
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[4]  K.J. Henrickson, C.B. Hall, Diagnostic assays for respiratory syncytial virusNot admitted 47/162 (29) 17/42 (40) –
alse-positive cases. For BNR six patients were admitted to the PICU
6/42, 14%) despite a false-negative test result. None of the ﬁve BNR
alse-positive tested patients were admitted to the PICU (0/5).
. Discussion
The present study evaluated the diagnostic performance of
NI and BNR RADTs in a large number of symptomatic paediatric
atients between 0 and 5 years attending our tertiary care pae-
iatric hospital during almost eight consecutive years. By testing
resh nasal washings with RT-PCR, we found a relatively low sensi-
ivity and PPV for BNI. The overall test performance of BNR scored
igher for all these aspects. Both BNI and BNR false-negative cases
isplayed a signiﬁcantly higher Ct-value compared to all RT-PCR
ositive and true-positive tested cases.
The accuracy of rapid tests is generally less than that of RT-PCR
nd virus isolation assays. However, RADTs are valuable as a
oint-of-care test for their ease of use, fast results and laboratory
ndependence [8]. These advantages, and especially the high speci-
city are important for their use as surveillance tools for inﬂuenza
utbreaks as recommended by the World Health Organization [8].
ndeed for surveillance purpose a high speciﬁcity is of importance,
hich we found to be the case in our study. However, for clinical
anagement this is not sufﬁcient. In theory, the decision to start
ntiviral therapy and to refrain from unnecessary further diagnos-
ic testing and antibiotic use may  be based on RADT [16–18]. In
ddition, rapid test results may  result in more effective isolation
nd containment measures [6]. For this purpose assay sensitivity
s of utmost importance. Therefore, we conclude that the relatively
ow sensitivity of the BNI in our tertiary care centre is worrisome.
f note, BNR test performance proved to be better compared to
he BNI, although false-negative cases were detected. Based on our
esults we stopped using BNI and will use rapid PCR-based tests for
etection of inﬂuenza virus and RSV.
We considered the clinical implications of a false-negative and
alse-positive test result in relation to hospitalization and found no
igniﬁcant differences between these groups and RT-PCR positive
nd BNI positive tested cases, indicating that the clinical observa-
ion is still pivotal in admission decision-making as suggested by
urrent guidelines. In the present study we were not able to study
ffects of testing on treatment since antiviral medication was not
outinely used in our hospital before 2009. Data on isolation and
ontainment measures were not available.
Although the retrospective nature of our study has inherent lim-
tations, we were able to include more than 500 samples of patients
ver time. Since, our study spanned a considerably longer period
f time than previous studies, we were able to test the clinical fea-
ibility of RADTs “in a real life” clinical setting and for different
irculating virus subtypes during eight consecutive seasons. Over-
ll, most studies reported a high speciﬁcity and high NPV versus a
ow sensitivity and low PPV for BNI, which is largely in agreement
ith our results [5–7,9–12]. We  did ﬁnd a relatively high sensitivitycal Virology 79 (2016) 12–17
of 79% and an even higher PPV (97%) for BNR, which is in agreement
with data obtained in other studies [5,19,20].
During the last decade, RT-PCR has become the gold standard
for detecting the presence of respiratory viruses [4]. The down-
side of RT-PCR is the relatively long time (6–24 h) between sample
collection and availability of test results [21]. This makes cur-
rent RT-PCR formats less useful for admission decision-making
and calls for faster methods. Indeed, new rapid point-of-care PCRs
are being developed and implemented with a shorter turnaround
time [22–27]. Studies comparing their performances with those
of RT-PCR would allow us to judge their potential for clinical
decision-making.
In conclusion, we evaluated the performance of the RADTs BNI
and BNR in a tertiary care paediatric hospital setting over eight
consecutive years. We  showed that sensitivity and PPV of BNI
were relatively low (69% and 55%), whereas those of BNR were
higher (79% and 97%) when compared to the respective gold stan-
dard RT-PCR. False-negative samples consistently displayed high
Ct-values, although this did not inﬂuence whether patients were
hospitalized or not. Given the relatively low sensitivity and PPV of
the BNI we strongly advocate a restricted use of BNI or similar rapid
inﬂuenza antigen detection assays in a tertiary paediatric care set-
ting. In contrast, the higher sensitivity and PPV of the BNR rendered
this rapid test more useful, albeit still less sensitive than RT-PCR.
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